The administration with 18α-GA can prevent the invasion of DU-145 prostate cancer cells by downregulating the levels of NF-ĸB (p65), VEGF and MMP-9, as well as HMGB1 and IL-6 (Shetty et al., 2011). Here, VEGFA is linked to prostate carcinoma.